Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 17, 2017The LancetOpen Access

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

View Full Paper
Ask AI
Bookmark
Share

Authors

David Cameron
David CameronBrighton and Sussex Medical School
Martine Piccart
Martine PiccartUniversité Libre de Bruxelles
Richard D. Gelber
Richard D. GelberHarvard University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cameron et al. (2017) studied this question.

synapsesocial.com/papers/6a7eb3a4400aca267ab99203https://doi.org/10.1016/s0140-6736(16)32616-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer2005 · 5,139 citations
  2. 2Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer2005 · 5,379 citations
  3. 3Adjuvant Trastuzumab in HER2-Positive Breast Cancer2011 · 2,793 citations
  4. 4Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-312011 · 718 citations
  5. 5Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System2007 · 896 citations